目的：原发性中枢神经系统淋巴瘤（PCNSL）诊断的金标准是立体定向活检后的组织病理学诊断。然而，PCNSL有多学科诊断工作，这与诊断延迟有关，并可能导致治疗延迟。本文为参与PCNSL患者（新型）诊断和护理的临床决策的神经外科医生提供建议，旨在提高PCNSL患者诊断过程的统一性和及时性。
方法：我们提出了一个小型综述，以讨论立体定向活检在PCNSL诊断新发展的背景下的作用。以及细胞减灭术的作用。
结果：基于脑脊液的诊断是辅助诊断，不能取代基于立体定向活检的诊断。
结论：脑立体定向活检后的组织病理学诊断仍然是诊断的金标准。额外的诊断不应是诊断延迟的原因。目前没有足够的证据支持PCNSL的细胞减灭术，最近的研究显示矛盾的数据和次优的研究设计。
OBJECTIVE: The gold standard for diagnostics in primary central nervous system lymphoma (PCNSL) is histopathological diagnosis after stereotactic biopsy. Yet, PCNSL has a multidisciplinary diagnostic work up, which associated with diagnostic delay and could result in treatment delay. This article offers recommendations to neurosurgeons involved in clinical decision-making regarding (novel) diagnostics and care for patients with PCNSL with the aim to improve uniformity and timeliness of the diagnostic process for patients with PCNSL.
METHODS: We present a mini review to discuss the role of stereotactic biopsy in the context of novel developments in diagnostics for PCNSL, as well as the role for cytoreductive surgery.
RESULTS: Cerebrospinal fluid-based diagnostics are supplementary and cannot replace stereotactic biopsy-based diagnostics.
CONCLUSIONS: Histopathological diagnosis after stereotactic biopsy of the brain remains the gold standard for diagnosis. Additional diagnostics should not be a cause of diagnostic delay. There is currently no sufficient evidence supporting cytoreductive surgery in PCNSL, with recent studies showing contradictive data and suboptimal study designs.
PDF(Pubmed)